Navigation Links
Ono Pharmaceutical Selects Genedata Expressionist for Mass Spectrometry
Date:2/7/2013

Basel (Switzerland) and Tokyo (Japan) (PRWEB) February 07, 2013

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Ono Pharmaceutical Co., Ltd.. (Ono) extended its Genedata collaboration with a license of Genedata Expressionist for Mass Spectrometry. Ono is a leading R&D-oriented international pharmaceutical company, which provides treatments for oncological and cardiovascular diseases. The Genedata Expressionist system, an enterprise and comprehensive platform for omics data management, will be used by Ono to further strengthen its targeted proteomics and metabolomics research.

“Our daily research demands accurate mass profiling analysis as well as powerful MRM capabilities for effective quantitative analysis,” noted a spokesperson for the Tsukuba Research Institute at Ono. “Genedata Expressionist for Mass Spectrometry supports our proteomics and metabolomics research with a sophisticated data analysis platform that can process chromatograms ranging from 2MB to over 1GB. And, the system’s ability to integrate data from a variety of instruments is a valuable benefit to us. Finally, with Genedata Expressionist we can rely on superior algorithms that generate clinically relevant biomarkers supporting efficient research processes.”

Experimental designs of molecular profiling studies in the life sciences are continually growing in complexity and size. Genedata Expressionist analyzes and manages genomic, transcriptomics, proteomics, metabolomics, and epigenomics data from leading technologies including next-generation sequencing, high-density microarrays, RT-PCR, and other genomic tools. Additionally, Genedata Expressionist enables integrated analysis and management of all major mass spectrometry (MS) profiling applications including a comprehensive solution for proteomic, metabolomics, and lipidomics data from all major MS technologies. With robust support of MRM data, the system’s innovative capabilities include:

  •     Data Visualization
  •     Background Subtraction
  •     Grid Alignment
  •     Peak Detection
  •     Annotation

“We are proud of our collaboration with Ono, one of the world’s leading pharmaceutical companies providing innovative drug therapies,” said Dr. Othmar Pfannes, CEO of Genedata. “With Genedata Expressionist and its support of innovative technologies such as MS and next-generation sequencing, we provide an integrative computational platform that supports customers such as Ono who are pioneering novel therapies. And, we are committed to continuous innovation by expanding the scope Genedata Expressionist applications in areas such as molecular diagnostics and personalized healthcare.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. http://www.genedata.com.

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10357457.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Packaging Machinery Manufacturer, Sepha Ltd.Reports Record Year for Sales of its Visionscan Leak Detection Machine and its Pharmaceutical Deblistering Equipment
2. DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
3. Oramed Pharmaceuticals Announces Reverse Stock Split
4. Todays Research on Mylan and Watson Pharmaceuticals: One Drug Makers Sorrow is Another Ones Joy
5. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
6. Eckert & Ziegler Vitalea Science and Korea-based BioCore Bring Human Microdosing to Korea to Address the Needs of the Emergent Pharmaceutical Industry
7. UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
8. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
9. Asia-Pacific Active Pharmaceutical Ingredients (APIs) Market Analysis & Forecasts to 2017 in New Research Report @ RnRMarketResearch.com
10. Rafarma Pharmaceuticals, Inc. Achieves Full Certification
11. K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... the launch of the Supplyframe Design Lab . Located in Pasadena, Calif., ... the future of how hardware projects are designed, built and brought to market. ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. Stock-Callers.com has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):